Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point ...

CompanyOverview|NASDAQ:TEM] Tempus AI (NASDAQ: TEM) is an interesting AI story that operates a platform and library for ...

The tech industry has been so excited about generative AI that everyone seems to miss a fundamental point: it’s not at all ...

We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where ...

In a latest program on CNBC, Jim Cramer expressed his renewed optimism for major tech stocks and said the negative market ...

Tempus AI shares rose after a Q1 beat, as an analyst highlighted its AI-driven growth, expanding pharma deals, and $1B+ ...

Adjusted EBITDA improved significantly to $-16.2 million compared to $-43.9 million in Q1 2024, representing a $27.8 million ...

We recently published a list of 12 Most Popular Stocks on Robinhood in 2025. In this article, we are going to take a look at ...

Nancy Pelosi's newest stock bet, Tempus AI, remains an enticing buy following a promising Q1 2025 earnings report.

Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...

The firm's Genomics revenues increased 89 percent, while Data and Services revenues rose 43 percent year over year.

Lefkofsky announced a three-year, $200 million data and modeling license agreement with AstraZeneca and Pathos to build the world’s largest foundation model in oncology. This agreement increased ...